PER977

01/01/2021 - "Ciraparantag, given after the bleeding injury, also significantly reduced blood loss. "
08/01/2019 - "Because it is so broadly applicable, ciraparantag might be a good future option for the management of most bleeding complications under anticoagulant treatment. "
11/01/2016 - "However, andexanet alfa, a recombinant modified FXa decoy molecule, is in a late-phase clinical trial in bleeding patients, and ciraparantag, a small molecule that appears to reverse many anticoagulants including the FXa inhibitors, is in development. "
01/01/2021 - "In animal models of bleeding (rat tail transection and liver laceration), a single IV dose of ciraparantag given at peak concentrations of the anticoagulant, but before the bleeding injury, significantly reduced the blood loss. "
01/01/2020 - "This review summarizes the current evidence about three reversal agents idarucizumab, andexanet alfa and ciraparantag, and the use of the first two in the emergency setting in patients with active major bleeding or who need urgent surgery which physicians indicate for a better management approach in order to increase patient's safety. "

01/01/2017 - "Potentially related adverse events were periorbital and facial flushing and cool sensation following IV injection of ciraparantag. "
03/07/2022 - "Adverse events related to ciraparantag were mild, transient hot flashes or flushing. "

01/01/2021 - "In animal models of bleeding (rat tail transection and liver laceration), a single IV dose of ciraparantag given at peak concentrations of the anticoagulant, but before the bleeding injury, significantly reduced the blood loss. "

03/07/2022 - "Adverse events related to ciraparantag were mild, transient hot flashes or flushing. "